AML-545 Long-Term Follow-up Demonstrates Ongoing Efficacy Benefit of 131I-Apamistamab-led Allogeneic Hematopoietic Cell Transplantation in Older Patients With Active, R/R AML in the Phase 3 SIERRA Trial
Year: 2024
Type: conference-abstract
Authors: Stuart Seropian, Boglarka Gyurkocza, Rajneesh Nath, Hannah Choe, Mark Litzow, Camille Abboud, Nebu Koshy, Patrick Stiff, Benjamin Tomlinson, Sunil Abhyankar, James Foran, Sameem Abedin, George Chen, Zaid Al-Kadhimi, Partow Kebriaei, Mitchell Sabloff, Johnnie Orozco, Katarzyna Jamieson, Margarida Silverman, Koen Van Besien, Michael Schuster, Arjun Law, Sebastian Mayer, Hillard Lazarus, Jennifer Spross, Kate Li, Madhuri Vusirikala, Brenda Sandmaier, John Pagel, Avinash Desai, Sergio Giralt
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4401876116